# Profound Medical Corp.: overview PROF · Nasdaq · CIK 1628808 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/prof.md) · [Financials](/companies/prof/financials.md) · [Filings](/companies/prof/filings.md) · [Insiders](/companies/prof/insiders.md) Latest reported revenue: [$2.5m](/filings/0001104659-26-092066.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-092066). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,542](/filings/0001104659-25-111378.md) | [4,026 d](/filings/0001410578-25-000300.md) | [2,341](/filings/0001410578-25-001112.md) | [1,981](/filings/0001410578-25-001809.md) | [5,059](/filings/0001104659-25-111378.md) | [6,717 d](/filings/0001104659-26-024153.md) | [5,337](/filings/0001104659-26-057198.md) | [2,483](/filings/0001104659-26-092066.md) | | Gross margin | % | [70.3%](/filings/0001104659-25-111378.md) | [73.6% d](/filings/0001104659-26-024153.md) | [79.2%](/filings/0001104659-26-057198.md) | [81.7%](/filings/0001104659-26-092066.md) | [77.7%](/filings/0001104659-25-111378.md) | [59.4% d](/filings/0001104659-26-024153.md) | [71.8%](/filings/0001104659-26-057198.md) | [78.4%](/filings/0001104659-26-092066.md) | | Operating margin | % | [(354.0%)](/filings/0001104659-25-111378.md) | [(207.3%) d](/filings/0001104659-26-024153.md) | [(477.0%)](/filings/0001104659-26-057198.md) | [(696.9%)](/filings/0001104659-26-092066.md) | [(176.2%)](/filings/0001104659-25-111378.md) | [(109.7%) d](/filings/0001104659-26-024153.md) | [(150.3%)](/filings/0001104659-26-057198.md) | [(445.7%)](/filings/0001104659-26-092066.md) | | Net margin | % | [(368.4%)](/filings/0001104659-25-111378.md) | [(122.9%) d](/filings/0001104659-26-024153.md) | [(458.1%)](/filings/0001104659-26-092066.md) | [(792.3%)](/filings/0001104659-26-092066.md) | [(157.7%)](/filings/0001104659-25-111378.md) | [(121.7%) d](/filings/0001104659-26-024153.md) | [(132.2%)](/filings/0001104659-26-092066.md) | [(384.2%)](/filings/0001104659-26-092066.md) | | Diluted EPS | $ per share | [0.38](/filings/0001104659-25-111378.md) | not reported | [0.36](/filings/0001104659-26-057198.md) | [(0.52)](/filings/0001104659-26-092066.md) | [0.26](/filings/0001104659-25-111378.md) | not reported | [0.19](/filings/0001104659-26-057198.md) | [(0.26)](/filings/0001104659-26-092066.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.9](/filings/0001410578-23-000212.md) | [6.7](/filings/0001410578-24-000149.md) | [5.9](/filings/0001410578-25-000300.md) | [9.7](/filings/0001410578-25-000300.md) | [16.1](/filings/0001104659-26-024153.md) | | Gross margin | % | [43.0%](/filings/0001410578-23-000212.md) | [45.2%](/filings/0001410578-24-000149.md) | [73.1%](/filings/0001410578-25-000300.md) | [72.2%](/filings/0001104659-26-024153.md) | [70.8%](/filings/0001104659-26-024153.md) | | Operating margin | % | [(440.7%)](/filings/0001410578-23-000212.md) | [(480.9%)](/filings/0001410578-24-000149.md) | [(485.7%)](/filings/0001410578-25-000300.md) | [(339.4%)](/filings/0001104659-26-024153.md) | [(256.3%)](/filings/0001104659-26-024153.md) | | Net margin | % | [(446.7%)](/filings/0001410578-23-000212.md) | [(429.1%)](/filings/0001410578-24-000149.md) | [(480.1%)](/filings/0001410578-25-000300.md) | [(285.6%)](/filings/0001104659-26-024153.md) | [(264.4%)](/filings/0001104659-26-024153.md) | | Diluted EPS | $ per share | [1.50](/filings/0001410578-23-000212.md) | [1.38](/filings/0001410578-24-000149.md) | [1.34](/filings/0001410578-25-000300.md) | [1.12](/filings/0001104659-26-024153.md) | [1.41](/filings/0001104659-26-024153.md) | | Free cash flow | $m | [(22.4)](/filings/0001410578-23-000212.md) | not reported | not reported | not reported | [(38.4)](/filings/0001104659-26-024153.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue; Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue; Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prof/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FIL Ltd](/funds/318989.md) | 2026-06-30 | $15.8m | 2,370,000 | | Added +30,000 | | [GAGNON SECURITIES LLC](/funds/1125725.md) | 2026-06-30 | $13.0m | 1,960,074 | | Added +15,750 | | [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $8.0m | 1,199,564 | | Added +83,216 | | [Timelo Investment Management Inc.](/funds/1851296.md) | 2026-06-30 | $7.4m | 1,114,967 | | Unchanged | | [Gagnon Advisors, LLC](/funds/1599466.md) | 2026-06-30 | $6.4m | 962,186 | | Unchanged | | [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $5.5m | 828,118 | | Unchanged | | [Z3 Capital Partners, LLC](/funds/2127787.md) | 2026-06-30 | $5.5m | 820,941 | | Added +2,950 | | [LETKO, BROSSEAU & ASSOCIATES INC](/funds/1297496.md) | 2026-06-30 | $5.4m | 935,725 | | Reduced −17,450 | | [MMCAP International Inc. SPC](/funds/1304857.md) | 2026-06-30 | $4.5m | 671,356 | | Reduced −73,796 | | [ARDSLEY ADVISORY PARTNERS LP](/funds/900529.md) | 2026-06-30 | $3.8m | 575,000 | | Unchanged | ## Recent filings [All 285 filings](/companies/prof/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 20:45 ET | [8-K](/filings/0001171843-26-006781.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-006781 | | 2026-10-14 | 12:00 ET | [8-K](/filings/0001171843-26-006615.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-006615 | | 2026-10-09 | 17:11 ET | [8-K](/filings/0001171843-26-006559.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-006559 | | 2026-10-07 | 20:45 ET | [8-K](/filings/0001171843-26-006499.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-006499 | | 2026-09-04 | 01:00 ET | [8-K](/filings/0001171843-26-005884.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-005884 | | 2026-09-03 | 11:07 ET | [8-K](/filings/0001171843-26-005868.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-005868 | | 2026-08-17 | 12:35 ET | [8-K](/filings/0001171843-26-005580.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-005580 | | 2026-08-17 | 11:30 ET | [8-K](/filings/0001171843-26-005575.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-005575 | | 2026-08-13 | 20:30 ET | [8-K](/filings/0001171843-26-005500.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-005500 | | 2026-08-06 | 20:32 ET | [10-Q](/filings/0001104659-26-092066.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092066 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-024153.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1628808 - Tickers: PROF - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: A6 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.